Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
Voom has developed a multi-platform wellness program to address both the injuries ...
Voom has developed a multi-platform wellness pr...
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...
Ovid Therapeutics is a biopharmaceutical compan...
Abeona Therapeutics is focused on developing and delivering gene therapy products ...
Abeona Therapeutics is focused on developing an...
Join the National Investor Network and get the latest information with your interests in mind.